Triclabendazole for the treatment of fascioliasis and paragonimiasis

Bibliography

• WHO: Control of foodborne trematode infections. Report of a WHO study group. WHO Technical Report Series No. 849. World Health Organization, Geneva (1995).
   Google Scholar
• ••Authoritative review covering all aspects ofthe epidemiology and control of food-borne trematodiasis as of the early 1990s.
   Google Scholar
• KEISER J, UTZINGER J: Emerging foodborne trematodiasis. Emerg. Inf Dis. (2005) 11:1507–1514.
   PubMed Web of Science ®Google Scholar
• ESTEBAN J-G, GONZALEZ C, CURTALE F et al.: Hyperendemic fascioliasis associated with schistosomiasis in villages in the Nile Delta of Egypt. Am. J. Trop. Med. Hyg. (2003) 69:429–437.
   PubMed Web of Science ®Google Scholar
• KEISER J, UTZINGER J: Chemotherapy for major food-borne trematodes: a review. Expert Opin. Pharmacother. (2004) 5:1711–1726.
   PubMed Web of Science ®Google Scholar
• •Provides an overview of the current landscape of drugs used for the treatment of major food-borne trematode infections in humans.
   Google Scholar
• MAS-COMA S: Human fascioliasis: patterns in human endemic areas of South America, Africa and Asia. Southeast Asian J. Trop. Med. Public Health (2004) 35:1–11.
   Google Scholar
• •Provides detailed information on clinical and epidemiological aspects of fascioliasis.
   Google Scholar
• SAFAR E, MIKHAIL E, BASSIOUNI G, EL-BASSIOUNI S, EL-KHOLY H: Human fascioliasis in some areas in Cairo and Giza Governorates, Egypt. J. Egypt. Soc. ParasitoL (2005) 35:181–192.
   PubMedGoogle Scholar
• MARCOS L, MACO V, SAMALVIDES F, TERASHIMA A, ESPINOZA JR, GOTUZZO E: Risk factors for hepatica infection in children: a-control study. Trans. R. Soc. Trop. Med. Hyg. (2005) (In Press).
   Google Scholar
• CHOI WY: Paragonimus westermani: pathogenesis and clinical features of infection. Arzneimittelforschung (1984) 34:1184–1185.
   PubMed Web of Science ®Google Scholar
• HAS WELL-ELKINSM, LEVRI E: Food-borne trematodes. In: Manson's Tropical Diseases, Cook G, Zumla A (Eds), Saunders, London, UK (2003) 21:1471–1486.
   Google Scholar
• ••Excellent chapter with comprehensive up-to-date reviews on the major food-borne trematode infections.
   Google Scholar
• SHARMA DC: Paragonimiasis causing diagnostic confusion with tuberculosis. Lancet Infect. Dis. (2005) 5:538.
   Web of Science ®Google Scholar
• HAWN TR, JONG EC: Update on hepatobiliary and pulmonary flukes. Curr. Infra. Dis. Rep. (1999) 1:427–433.
   PubMedGoogle Scholar
• •A good review on the hepatobiliary and pulmonary flukes.
   Google Scholar
• APT W, AGUILERA X, VEGA F et aL: Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am. J. Trop. Med. Hyg. (1995) 52:532–535.
   PubMed Web of Science ®Google Scholar
• CHEN MG, MOTT K: Progress in assessment of morbidity due to Fasciola hepatica infection: a review of recent literature. Trop. Dis. Bull. (1990) 87:1–38.
   Google Scholar
• ROSSIGNOL JF, ABAZA H, FRIEDMAN H: Successful treatment of human fascioliasis with nitazoxanide. Trans. R. Soc. Trop. Med. Hyg. (1998) 92:103–104.
   PubMed Web of Science ®Google Scholar
• FAVENNEC L, JAVE ORTIZ J, GARGALA G et al.: Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment. PharmacoL Ther. (2003) 17:265–270.
   PubMed Web of Science ®Google Scholar
• WESSELY K, REISCHIG HL, M, STEMPKA R: Human treated with triclabendazole (Fasinex) for the first time. Trans. R. Soc. Trop. Med. Hyg. (1988) 82:743–744.
   PubMed Web of Science ®Google Scholar
• •The first study administering triclabendazole to humans.
   Google Scholar
• MASSOUD J: Fascioliasis outbreak of man and drug test (triclabendazole) in Caspaian littoral, northern part of Iran 1989. Proceedings of the 7th International Congress of Parasitology, Paris, France (1990):438.
   Google Scholar
• WHO: Essential medicines. WHO model list 14th edition. WHO Drug Information. World Health Organization, Geneva (2005).
   Google Scholar
• SAVIOLI L, CHITSULO L, A: New opportunities for control of fascioliasis. Bull. World Health Organ. (1999) 77:300.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Fasinex works - and that's no fluke. Ciba-Geigy J. (1985) 85.
   Google Scholar
• BENNETT JL, KOHLER P: hepatica: action in vitro of triclabendazole on immature and adult stages. Exp. ParasitoL (1987) 63:49–57.
   PubMed Web of Science ®Google Scholar
• ROBINSON CP: Triclabendazole. Drugs Today (1985) 21:227–233.
   Google Scholar
• •A comprehensive review on the veterinary use of triclabendazole.
   Google Scholar
• WHO: Triclabendazole and fascioliasis - a new drug to combat an age old disease. WHO factsheet No. 191. World Health Organization, Geneva (1998).
   Google Scholar
• FAIRWEATHER I, BORAY JC:: efficacy, actions, resistance and its management. Vet. J. (1999) 158:81–112.
   PubMed Web of Science ®Google Scholar
• •An excellent overview of the efficacies, mechanisms of action and resistance of the fasciocidal drugs that are used in veterinary practice.
   Google Scholar
• FAIRWEATHER I, BORAY JC: of fasciolide action and drug resistance in Fasciola hepatica. In: Fasciolosis. Dalton JP (Ed.), CABI Publishing, Dublin, Ireland (1999):225–276.
   Google Scholar
• •A comprehensive chapter on the mode of actions and drug resistance of fasciolicidal drugs.
   Google Scholar
• FAIRWEATHER I: Triclabendazole: new skills to unravel an old(ish) enigma. J. HelminthoL (2005) 79:227–234.
   PubMed Web of Science ®Google Scholar
• STITT AW, FAIRWEATHER I, MacKENDER RO: The effect of triclabendazole (Fasinex') on protein synthesis by the liver fluke, Fasciola hepatica. Int. J. ParasitoL (1995) 25:421–429.
   PubMed Web of Science ®Google Scholar
• OVEREND DJ, BOWEN FL: Resistance of Fasciola hepatica to triclabendazole. Aust. Vet. J. (1995) 72:275–276.
   PubMed Web of Science ®Google Scholar
• MITCHELL GB, MARIS L, WELL MA: Triclabendazole-resistant liver fluke in Scottish sheep. Vet. Rec. (1998) 143:399.
   PubMed Web of Science ®Google Scholar
• MOLL L, GAASENBEEK CP, VELLEMA P, BORGSTEEDE FH: Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in the Netherlands. Vet. ParasitoL (2000) 91:153–158.
   PubMed Web of Science ®Google Scholar
• WALKER SM, McKINSTRY B, BORAY JC et aL: Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. ParasitoL Res. (2004) 94:427–438.
   PubMed Web of Science ®Google Scholar
• ROBINSON MW, TRUDGETT A, HOEY EM, FAIRWEATHER I: Triclabendazole-resistant Fasciola hepatica: 0-tubulin and response to in vitro treatment with triclabendazole. Parasitology (2002) 124:325–338.
   PubMed Web of Science ®Google Scholar
• ROBINSON MW, LAWSON J, TRUDGETT A. HOEY EM, FAIRWEATHER I: The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. ParasitoL Res. (2004) 92:205–210.
   Google Scholar
• BOGAN JA, KINABO LD, MB, FORMICA C, P, ALVINERIE M: Pharmacokinetics of triclabendazole in cattle, sheep, goats, horses, ponies, donkeys, pigs and man. Proceedings of the 4th Congress of the European Association for Veterinary Pharmacology and Toxicology University of Veterinary Science, Budapest, Hungary (1988):159–163.
   Google Scholar
• LOUTAN L, BOUVIER M, B et al.: Single treatment of invasive fascioliasis with triclabendazole. Lancet (1989) 334:383.
   Google Scholar
• DE RONDE T, MELANGE M, VAN BEERS B et aL: Distomatosis of the bile ducts. Value of retrograde cholangiography. Efficacy of triclabendazole. Acta Clin. Belg. (1992) 47:209–214.
   PubMed Web of Science ®Google Scholar
• LECAILLON JB, GODBILLON J, CAMPESTRINI J et aL: Effect of food on the bioavailability of triclabendazole in with fascioliasis. Br. J.. Pharmacol (1998) 45:601–604.
   Web of Science ®Google Scholar
• HENNESSY DR, LACEY E, STEEL JW, PRICHARD RK: The kinetics of triclabendazole disposition in sheep. J. Vet. Pharmacol Ther. (1987) 10:64–72.
   PubMed Web of Science ®Google Scholar
• McKELLAR QA, KINABO LD: The pharmacology of flukiciclal drugs. Br. Vet. J. (1991) 147:306–321.
   PubMedGoogle Scholar
• WHO: Evaluation of certain veterinary drug residues in food. WHO Technical Report Series No. 832. World Health Organization, Geneva (1993).
   Google Scholar
• YOSHIMURA H: Teratogenic evaluation of triclabendazole in rats. Toxicology (1987) 43:283–287.
   PubMed Web of Science ®Google Scholar
• COLES GC: Anthelmintic activity of triclabendazole. j Helminthol (1986) 60:210–212.
   PubMed Web of Science ®Google Scholar
• SUHARDONO D: Triclabendazole against Fasciola hepatica infections in rats. University of Liverpool, MVS Thesis. Liverpool, UK (1987).
   Google Scholar
• OLAECHEA FV: Trematode infections in the definitive host: studies on diagnosis, treatment, control and parasite/toxin interactions. PhD Thesis. Royal Veterinary and Agricultural University and Danish Bilharziasis Laboratory, Copenhagen, Denmark (1989).
   Google Scholar
• GUPTA SC, CHANDRA R, YADAV SC: Efficacy of triclabendazole against experimental Fasciola gigantica infection in sheep, goat, buffalo and rabbit: a comparative study. Indian Vet. J. (1989) 66:680–682.
   Web of Science ®Google Scholar
• ESTUNINGSIH SE, STEVENSON P, BERIAJAYA, KNOX MR: Triclabendazole in the treatment of Fasciola gigantica infection in swamp buffalo (Bubalus bubalis). Aust. Vet. J. (1990) 67:234–235.
   PubMed Web of Science ®Google Scholar
• YAHIRO S, HABE S: Experimental chemotherapeutic studies of westermani and P ohirai.. Bull. Fukuoka Univ. (1996) 23:21–25.
   Google Scholar
• LIU Y, GAO J, WANG X, YU D, SU Q:Experimental observation of effects of triclabendazole on Paragonimus westermani infection in dogs. Chin. Med. J. (1999) 112:345–348.
   PubMed Web of Science ®Google Scholar
• GAO J, LIU Y, WANG X, HU P: Triclabendazole in the treatment of Paragonimiasis skrjabini. Chin. Med. J. (2003) 116:1683–1686.
   PubMed Web of Science ®Google Scholar
• WEBER P, BC-SCHER G, BUTTNER DW: The effects of on the lung fluke, Paragonimus uterobilateralis in the experimental host Sigmodon hispidus. Trop. Med. Parasitol. (1988) 39:322–324.
   PubMedGoogle Scholar
• GAO JS: Experimental observation of treating dogs infected with sinensis with praziquantel and triclabendazole. Chin. J. Parasit.. Control (1998) 11:357.
   Google Scholar
• SHIRAMIZU K, ABU M, HARA Y, HAIDA K: The effect of triclabendazole on canine clonorchiasis. Yamaguchi J. Vet. Med. (1989) 16:113–116.
   Google Scholar
• KOTEENIKOV GA, VARENICHEV AA: Development of efficient anthelminthic drugs for domestic carnivorous animals-definitive hosts of Opisthorchis.. Parazitol (1988) 2:24–26.
   Google Scholar
• KHALIL SS: On the schistosomicidal effect of triclabendazole an experimental study. J. Egypt. Soc. Parasitol (2000) 30:799–808.
   PubMedGoogle Scholar
• AGRAWAL MC, GEORGE J, GUPTA S: Chemotherapeutic trials using Schistosoma incognitum mouse model. Parasit. Dis. (1999) 23:137–138.
   Google Scholar
• TALAIE H, EMAMI H, D et al.: Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis. Clin. Exp. Pharmacol Physiol (2004) 31:777–782.
   PubMed Web of Science ®Google Scholar
• LABURTE C, MOTT K, MULL R, SEVERNE Y: Triclabendazole for fascioliasis: efficacy and tolerability of a single dose treatment. In: Infectious Diseases and Public Health, Angelico M, Rocchi G (Eds), Balaban Publishers, L'Aquila, Italy (1998):325–333.
   Google Scholar
• RIPERT C, COUPRIE B, MOYOU R, GAILLARD F, APPRIOU M, TRIBOULEY-DURET J: Therapeutic effect of triclabendazole in patients with paragonimiasis in Cameroon: a pilot study. Trans. R. Soc. Trop. Med. Hyg. (1992) 86:417.
   PubMed Web of Science ®Google Scholar
• CALVOPIICIA M, PAREDES W, GUDERIAN RH, POLTERA AA: Eficacia del triclabendazole en paragonimiasis pulmonar humana refractaria a la emetina, bithional y praziquantel. Parasitol al dia (1993) 17:44–46.
   Google Scholar
• CALVOPIICIA M, GUDERIAN RH, PAREDES W, CHICO M, COOPER PJ: Treatment of human pulmonary paragonimiasis with triclabendazole: clinical and drug efficacy. Trans. R. Soc.. Med. Hyg. (1998) 92:566–569.
   PubMed Web of Science ®Google Scholar
• CALVOPIICIA M, GUDERIAN RH, PAREDES W, COOPER PJ: Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. Trans. R. Soc. Trop. Med. Hyg. (2003) 97:451–454.
   PubMed Web of Science ®Google Scholar
• CURTALE F, HASSANEIN YA, L: Control of human fascioliasis by selective chemotherapy: design, cost and effect of the first public health, school-based intervention implemented in endemic areas of the Nile Delta, Egypt. Trans. R. Soc. Trop. Med. Hyg. (2005) 99:599–609.
   PubMed Web of Science ®Google Scholar
• •An important study underscoring the great potential of triclabendazole in a morbidity-based control approach at the community level.
   Google Scholar
• ISHII Y, NAKAMURA-UCHIYAMA F, NAWA Y: A praziquantel-ineffective fascioliasis case successfully treated with triclabendazole. Parasitol Int. (2002) 51:205–209.
   PubMed Web of Science ®Google Scholar
• WEGNER DH: The profile of the trematodicidal compound praziquantel. Arzneimittelfbrschung (1984) 34:1132–1136.
   PubMed Web of Science ®Google Scholar
• ABDUSSALAM M, KÄFERSTEIN FK, MOTT KE: Food safety measures for the control of foodborne trematode infections. Food Control (1995) 6:71–79.
   Web of Science ®Google Scholar
• •Good review on food safety measures and the research needs for the prevention and control of food-borne trematodiasis.
   Google Scholar
• EL SAYAD MH: Comparative studies on the effect of bithionol, praziquantel and triclabendazole in rabbit's fascioliasis. J. Egypt. Soc. Parasitol (1997) 27:925–926.
   PubMedGoogle Scholar
• SABA R, KORKMAZ M, INAN D et al.: Human fascioliasis. Clin. Microbiol (2004) 10:385–387.
   Web of Science ®Google Scholar
• YILMAZ H, ONER AF, AKDENIZ H, ARSLAN S: The effect of triclabendazole (Fasinex) in children with fasciolosis. J. Egypt. Soc. Parasitol (1998) 28:497–502.
   PubMedGoogle Scholar
• KABAALIOGLU A. CEKEN K, SABA R, ARTAN R, CEVIKOL C, YILMAZ S: Pediatric fascioliasis: report of three cases. Turk. J. Pediatr. (2003) 45:51–54.
   PubMed Web of Science ®Google Scholar
• METTER K, GLOSER H, VON GAISBERG U: Fascioliasis after a stay in Turkey. Dtsch. Med. Wschr. (2000) 125:1160–1163.
   PubMed Web of Science ®Google Scholar
• NEAU D, LAHARIE D, LIEFERMAN F et al.: Treatment of human fascioliasis with triclabendazole. 37th Interscience Conference 1524Expert Opin. Investig. Drugs (2005) 14(12)
   Google Scholar
• LOPEZ-VELEZ R,-CASTELLANO A, GARRON C: Successful treatment of human fascioliasis with triclabendazole. Eur. J. Clin. MicrobioL Infect. Dis. (1999) 18:525–526.
   PubMed Web of Science ®Google Scholar
• BECHTEL U, FEUCHT HE, HELD E, VOGL T, NOTHDURFT HD: Fasciola hepatica infection in a family: diagnosis and therapy. Dtsch. Med. Wschr. (1992) 117:978–982.
   PubMed Web of Science ®Google Scholar
• LE BRAS M, BEYLOT J, BIESSY H et al.: of human fasciolosis with triclabendazole. Med. Chir. Dig. (1989) 18:477–479.
   Google Scholar
• GUICHARD D, FLORI P, H, GALLOT B, LANG B, TRAN MANH SUNG R: Distomatose Fasciola hepatica. A propos de quatre observations en Haute-Loire.. Mal. Infect. (2002) 32:190–195.
   Google Scholar
• COUTURIER F, HIAR I, Y, CHRISTMANN D: Place du triclabendazole dans le traitement des fascioloses hepatiques. Med. Mal. Infect. (1999) 29:753–757.
   Google Scholar
• MARKWALDER K, KOLLER M, GOEBEL N, WOLFF K: Fasciola hepatica infection. Successful therapy using triclabendazole. Schweiz Med. Wochenschr. (1988) 118:1048–1052.
   PubMedGoogle Scholar
• HELFENSTEIN E, KAYSER S, LOCHER G: Human fascioliasis symptoms. A case report with review of the literature. Schweiz Rundsch. Med. Prax. (2000) 89:1427–1435.
   Google Scholar
• CAMINAL MONTERO L, FERNANDEZ FERNANDEZ C, QUIROS JF, PARRA F: The treatment of human fascioliasis with triclabendazole. Rev. Clin. Esp. (1999) 199:333–335.
   PubMedGoogle Scholar
• MERINO ALONSO J, GARCIA MJ, RUBIO L, RUIZ I: Human fascioliasis with atypical severe presentation. Treatment with triclabendazole. Enferm. Infec. MicrobioL Clin. (1998) 16:28–30.
   PubMedGoogle Scholar
• IGLESIAS ESCALERA G, PARDILLA Al, RODRIGO PALACIOS J et al.: Childhood hepatic fascioliasis treated with triclabendazole. An. Esp. Pediatr. (2002) 57:171–172.
   Google Scholar
• PICOT S, QUERREC M, GHEZ JL, GOULLIER-FLEURET A, GRILLOT R,-THOMAS P: A new report of triclabendazole efficacy during invading phase fasciolasis. Eur. j Clin. Microbiol. Infect. Dis. (1992) 11:269–270.
   PubMed Web of Science ®Google Scholar
• MONTEMBAULT S, SERFATY L, POIROT JL, WENDUM D, PENNA C, POUPON R: Hemorrhagic ascites disclosing massive Fasciola hepatica infection. GastroenteroL Clin. Biol. (1997) 21:785–788.
   PubMed Web of Science ®Google Scholar
• CHIRA 0, FLORESCU P, SPARCHEZ Z et al.: Acute Fasciola hepatica infection with severe presentation: a successful treatment triclabendazole. Rom. J. Gastroenterol.96.(2001) 10:321-324.
   Google Scholar
• DOHERTY JF, PRICE N, MOODY AH, SG, GLYNN MJ: Fascioliasis due to imported khat. Lancet (1995) 345:462.97. Antimicrobial Agents in Chemotherapy, Ontario, Canada (1997):379.
   Google Scholar
• MILLAN JC, MULL R, FREISE S, J: The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am. J. Trop. Med. Hyg-. (2000) 63:264-269.98.
   Google Scholar
• GRAHAM CS, BRODIE SB, PF: Imported Fasciola hepatica in the United States and treatment99.with triclabendazole. Clin. Infect. Dis. (2001) 33:1–5.
   PubMed Web of Science ®Google Scholar
• LAPOOK JD, MAGUN AM, KG, MELTZER JI: Sheep,100.watercress, and the Internet. Lancet (2000) 356:218.
   Google Scholar
• NOYER CM, COYLE CM, WERNER C, DUPOUY-CAMET J, TANOWITZ HB, M: Hypereosinophilia and liver101.mass in an immigrant. Am. J. Trop. Med. Hyg-. (2002) 66:774–776.
   PubMedGoogle Scholar
• LAIRD PP, BORAY JC: Human fascioliasis successfully treated with triclabendazole. Aust. N Z J. Med. (1992) 22:45–47.
   PubMedGoogle Scholar
• HUGHES AJ, SPITHILL TW,102. RE, BOUTLIS CS, PD: Human fasciolosis in an Australian urban setting.. J. Aust. (2003) 178:244–245.
   Google Scholar
• JAVE 0J, ALBAN OM, PC, SORIANO YS:103.Treatment of human hepatic fasciolasis with triclabendazole. Rev. GastroenteroL Peru (1999) 19:216–220.
   Google Scholar
• MINOPRIO JE, DONNA R, C et al.: A family outbreak104.of fluke infestation in humans of unusual distribution caused by Fasciola hepatica. Pren. Med. Argent. (1995) 82:869–877.
   Google Scholar
• MELERO M, RIGOU RC, LLOVERAS J, GENNARO 0: Hepatic fascioliasis. Uncommon cause of prolonged febrile syndrome with hypereosinophilia and hypodense images on computed tomography of the liver. Medicina (1991) 51:244–248.
   Google Scholar
• INCANI RN, VIEIRA JM, PACHECO M, S, AMARISTA M, LAZDINS J: Human infection by Fasciola hepatica in Venezuela: report of a geriatric case. Invest. Clin. (2003) 44:255–260.
   PubMedGoogle Scholar
• HADI S, CONTRERAS R, TOMBAZZI C, ALVAREZ M, MELENDEZ M: Hepatic fascioliasis: case report and review. Rev. Inst. Med. Trop. Sao Paulo (1996) 38:69–73.
   PubMedGoogle Scholar
• MORSHEDY H, FARGHALY A, SHARAF S, ABOU-BASHA L, BARAKAT R: Triclabendazole in the treatment of human fascioliasis: a community-based study. East. Mediterr. Health J. (1999) 5:888–894.
   PubMedGoogle Scholar
• Triclabendazole in the treatment of established human fascioliasis. East. Mediterr. Health J. (1998) 4:244–251.
   Google Scholar
• EL HODA M, EL SAYED IA, EL-SEDFY A: Effect of chronic fascioliasis on gall bladder and its management. J. Med. Res. Inst. (2000) 21:174–180.
   Google Scholar
• KARAKSY H, HASSANEIN B, OKASHA S, BEHAIRY B, GADALLAH I: Human fascioliasis in Egyptian children: successful treatment with triclabendazole.. Pediatr. (1999) 45:135–138.
   Web of Science ®Google Scholar
• ALLAM AF, SULTAN MM: The pulmonary performance and airway reactivity in acute and chronic fascioliasis before and after triclabendazole treatment. J. Egypt. Soc. ParasitoL (1997) 27:113–129.
   PubMedGoogle Scholar
• EL-MANSOURY ST, EL-AZZOUNI MZ, EL-GOHARI Y: Therapeutic effect of triclabendazole in patients with fascioliasis in Egypt. A preliminary study. J. Egypt. Soc. ParasitoL (1995) 25:137–143.
   PubMedGoogle Scholar
• HELMY M, MA: Studies of human fasciolosis in Egypt: some serum lipid parameters before and after treatment. J. Egypt. Soc. ParasitoL (1995) 25:769–772.
   PubMedGoogle Scholar
• NOZAIS JP, THOMAS I, BRICAIRE F, DANIS M, GENTILINI M: Apropos of 1 case of hepatogastric fascioliasis in Verde. Bull. Soc. Pathol. Exot. (1998) 91:148–150.
   PubMed Web of Science ®Google Scholar
• HU P, LIU YH: A clinical trial of triclabenciazole in the treatment of human paragonimiasis skrjabini. Chin. J. Parasit. Dis. Cont. (2001) 19:305–307.
   PubMedGoogle Scholar